Evaluation of disk susceptibility testing of fosfomycin tromethamine

Diagn Microbiol Infect Dis. 1993 Jul;17(1):67-70. doi: 10.1016/0732-8893(93)90073-g.

Abstract

Fosfomycin tromethamine is an orally administered fosfomycin that may be used for single-dose therapy of uncomplicated urinary tract infections. At breakpoint concentrations [< or = 128 micrograms/ml plus 25 micrograms/ml glucose-6-phosphate (G-6-P)], fosfomycin tromethamine inhibited > 90% of the 350 bacterial isolates tested. When testing Escherichia coli, Klebsiella spp., and Enterobacter spp., we note that the performance of fosfomycin disks improved when G-6-P was added to the disks. The interpretive error rates were minimized when 200-micrograms fosfomycin disks were supplemented with either 50 or 100 micrograms G-6-P. Using < or = 128 and > or = 256 micrograms/ml as the susceptible and resistant MIC breakpoints, respectively, the regression-analysis-derived disk diffusion zone diameter breakpoints for the 200-micrograms fosfomycin disk supplemented with 50 micrograms of G-6-P are as follows: susceptible, > or = 16 mm; intermediate, 13-15 mm; and resistant, < or = 12 mm.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bacteria / drug effects*
  • Evaluation Studies as Topic
  • Fosfomycin / analogs & derivatives*
  • Fosfomycin / pharmacology
  • Glucose-6-Phosphate
  • Glucosephosphates
  • Microbial Sensitivity Tests*
  • Regression Analysis
  • Tromethamine / analogs & derivatives*
  • Tromethamine / pharmacology
  • Urinary Tract / microbiology

Substances

  • Glucosephosphates
  • Tromethamine
  • Fosfomycin
  • Glucose-6-Phosphate